Thursday 9/21/17- Pre-market movers.
CCC, $21.35, Up 61 %. ITUS, $2.14, Up 10%.
Calgon Carbon Corporation (CCC) and
Kuraray Co., Ltd. (TYO:3405) announced today that their respective Boards of
Directors have unanimously approved, and the parties have entered into, a
definitive merger agreement under which Kuraray will acquire Calgon Carbon for
$21.50 per share in cash, which equates to an equity value of approximately
$1.1 billion, and a transaction value in excess of $1.3 billion, including
Calgon Carbon’s net indebtedness.
What They Do:
Calgon Carbon Corporation is a global leader in innovative solutions, high
quality products and reliable services designed to protect human health and
the environment from harmful contaminants in water and air.
Corporation (ITUS), Today provides a
corporate update before its Annual Meeting of Stockholders to be held on
September 22, 2017.
wholly owned subsidiary Anixa Diagnostics, recently renewed its research
agreement with The Wistar Institute for continued development of Cchek™, its
early cancer detection technology. Dr. Amit Kumar, President and CEO of ITUS
stated, "We continue to make progress in our R&D efforts as we work
with our partners, MD Anderson, U. Pennsylvania's Abramson Cancer Center,
Delaware Valley Urology, Virtua Hospitals, and others. Cchek™, which has
demonstrated 91% sensitivity and specificity in a preliminary study, continues
to perform at that level or better."
also recently announced the issuance of US Patent 9,739,783 covering its
technology for cancer detection. This ITUS patent was issued to inventors Dr.
Amit Kumar and John Roop, the CEO and VP of Engineering, respectively, of ITUS
What They Do:
ITUS, a cancer-focused biotechnology company, through its wholly owned
subsidiary, Anixa Diagnostics Corporation, is developing the Cchek™
platform, a series of non-invasive blood tests for the early detection of
solid tumor based cancers, which is based on the body's immunological response
to the presence of a malignancy.
Features available at SmallCapReview.com include in-depth profiles of select
Small-Cap/Penny Stocks as well as the most comprehensive and up to date news
available on the small-cap market.
No investor should assume that reliance on the views, opinions or
recommendations contained herein will produce profitable results. Nothing
within our site should be construed as an offer or solicitation to buy or sell
products or securities. The companies we profile may lack an active trading
market for their securities, investing in such securities is highly
speculative and carries a high degree of risk.
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on
small-caps, penny stocks and microcaps. SmallCapReview has built a loyal
opt-in following for their investor products by providing a newsletter at no
cost, sent to subscribers, highlighting select stocks in play.